What factors drove the changes in Koninklijke Philips's revenue and profit?

What does Koninklijke Philips do and what are its main business segments?

Did Koninklijke Philips beat or miss consensus estimates last quarter?

What were the key takeaways from Koninklijke Philips's earnings call?

What is the market's earnings forecast for Koninklijke Philips next quarter?

What were the key takeaways from Koninklijke Philips’s earnings call?

What is Koninklijke Philips's gross profit margin?

What guidance did Koninklijke Philips's management provide for the next earnings period?

- **Revenue Growth**: Q4 sales +7% YoY, driven by North America (+10% D&T, +14% Connected Care). Full-year +2.3% vs. 2025 outlook.
- **Margin Expansion**: Q4 EBITDA margin 15.1% (+160bps YoY). 2026 target 12.5-13%, despite €250-300M tariffs.
- **Innovation Success**: Personal Health margin 23% in Q4, up 500bps YoY, fueled by premium shavers and oral care.
- **2026 Outlook**: 3-4.5% sales growth, 2028 mid-teens margins. North America, international growth offset China cautiousness.
- **Risk Management**: €1.5B productivity program to offset tariffs. 2026 free cash flow €1.3-1.5B despite higher tax payments.

**【CEO Opening Remarks】**
- **Strong Q4 Performance**: Order intake up 7% YoY, driven by North America's double-digit growth in D&T and Connected Care. Full-year order intake +6%, exceeding 2025 outlook.
- **Margin Expansion**: Adjusted EBITDA margin improved 160bps to 15.1%, despite tariffs. Full-year margin 12.3%, above guidance.
- **Innovation Highlights**: Launches include helium-free MRI, AI-powered CT, and interventional navigation systems. SpectraWAVE acquisition strengthens cardiology leadership.
- **2026 Outlook**: Target 3-4.5% sales growth, mid-teens margin expansion by 2028. Focus on North America, international growth, and tariff mitigation.

**【CFO Financial Commentary】**
- **Segment Performance**: 
  - **D&T**: Q4 sales +4% YoY, Image-Guided Therapy (+10%) and Monitoring (+14%) lead. Full-year margin 11.7%, up 10bps.
  - **Connected Care**: Q4 sales +7%, Enterprise Informatics +12%. Full-year margin 10.7%, up 110bps.
  - **Personal Health**: Q4 sales +14%, driven by premium grooming and oral care. Full-year margin 18%, up 130bps.
- **Tariff Impact**: 2025 costs ~€200M, 2026 expected €250-300M. Mitigation efforts (localization, supply chain) to fully offset by 2028.
- **Cash Flow**: €512M free cash flow vs. €1B legal settlements. 2026 target €1.3-1.5B, supported by higher earnings and lower adjusting items.
- **Productivity**: €855M savings in 2025 (€2.5B+ since 2023). New €1.5B 2026-28 program to drive margin expansion.

**【Q&A Highlights】**
- **D&T Margin Drivers**: Innovation (AI, premium systems) and productivity offset tariffs. 2026 margin expansion to continue despite Q1 headwinds.
- **China Dynamics**: PH sales stabilizing, D&T cautious on tender execution. North America remains key growth engine.
- **Tariff Mitigation**: 2026 full-year impact, but 2028 mitigation plan on track. No material impact from Section 232 investigation yet.
- **Q1 2026 Phasing**: Lower end of 3-4.5% range due to seasonal factors and tariff timing. Margin dip expected but offset by 2025 productivity gains.

Koninklijke Philips N.V. (PHG) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 3% YoY comparable sales, driven by North America (8% order growth) and Personal Health (11% growth).
- **Margin Expansion**: Adjusted EBITDA margin up 50bps to 12.3%, with full tariff mitigation in Q3.
- **Cash Flow Strength**: Free cash flow of EUR 172M, on track for EUR 0.2-0.4B full-year target.
- **Strategic Moves**: USD 150M U.S. manufacturing investment to reduce tariff risk; AWS cloud partnership driving Connected Care growth.
- **Risk Management**: FDA warning letter remediation underway; no commercial impact expected.

**【CEO Summary Section】**
- **Order Momentum**: Q3 order intake grew 8%, marking the 4th consecutive quarter of improvement, driven by North America and Connected Care. Year-to-date orders are up 6%.
- **Revenue Performance**: Comparable sales growth stepped up to 3% YoY, with broad-based contributions from all segments. Personal Health led with 11% growth, while D&T and Connected Care grew 1% and 5%, respectively.
- **Margin Expansion**: Adjusted EBITDA margin expanded 50bps to 12.3%, despite full-quarter tariff impact. Gross margin improvements from new innovations offset cost headwinds.
- **Tariff Mitigation**: Full-year tariff impact expected at EUR 150-200M, with mitigation efforts (inventory management, exemptions) reducing impact in Q3.
- **FDA Update**: Received FDA warning letter but remains confident in remediation efforts; no commercial impact anticipated.

**【CFO Financial Commentary】**
- **Profitability**: GAAP net income of EUR 187M, Non-GAAP EPS of EUR 0.36 (13% YoY growth). Adjusted EBITDA margin improved 40bps YoY to 11.2%.
- **Productivity Savings**: Delivered EUR 222M in Q3, bringing YTD total to EUR 566M, on track for EUR 800M full-year target.
- **Cash Flow**: Free cash flow of EUR 172M (EUR 150M YoY improvement), with full-year guidance of EUR 0.2-0.4B.
- **Tariff Impact**: Q3 tariff impact fully offset, but annualized impact expected to weigh on 2026 margins.
- **FX Hedging**: No margin impact in Q3, but Q4 may see headwinds from currency volatility.

**【Q&A Highlights】**
- **Pricing Strategy**: Expect limited price hikes; innovation-driven margin expansion (e.g., AI-powered solutions) will be key.
- **China Dynamics**: Cautious outlook due to slow tender conversion, but no restocking; Personal Health growth offset D&T softness.
- **Tariff Mitigation**: 2026 reshoring investments (e.g., USD 150M in U.S. manufacturing) to reduce tariff exposure.
- **Connected Care Strength**: Hospital monitoring partnerships (e.g., AWS cloud migration) driving 5% sales growth and margin expansion.
- **Regulatory Engagement**: Advocating for tariff relief while maintaining quality compliance post-FDA warning letter.

Koninklijke Philips N.V. (PHG) Q3 2025 Earnings Call Transcript

- **Q2 Growth and Margin Expansion**: Comparable sales +1%, adjusted EBITA margin +130bps to 12.4%. Full year EBITA margin raised to 11.3-11.8% (up 50bps) on lower tariffs.
- **Segment Strength**: D&T order intake +double-digit in North America/Indonesia; Connected Care Monitoring partnerships driving Q3+ growth; Personal Health Europe/U.S. growth offset China destocking.
- **Tariff Impact**: €150-200M net impact in 2025, with Q3 margin decline expected. Long-term focus on mid-single-digit growth and mid-teens margins.
- **China Recovery**: PH destocking complete; medical equipment tenders slow but improving. Q2 sell-out up in festivals.

**【CEO Summary Section】**
- **Q2 Momentum and Outlook**: Order intake grew 6% (vs. 9% last year), with comparable sales up 1%. Full year sales growth outlook remains 1-3%, with adjusted EBITA margin raised to 11.3-11.8% (up 50bps) due to lower tariffs. Free cash flow guidance improved to €0.2-0.4 billion.
- **Segment Highlights**: 
  - **D&T**: Order intake up double-digit in North America and Indonesia, driven by Azurion systems and BlueSeal MR. Gross margin expanded 130bps to 13.5%.
  - **Connected Care**: Monitoring partnerships in North America offset high base; order book strong for Q3+.
  - **Personal Health**: Europe/U.S. growth offset China destocking; i9000 shavers and Sonicare launches driving momentum.
- **Tariff Mitigation**: €150-200M net impact in 2025, with Q3 margin expected to decline due to P&L lag. Long-term focus on mid-single-digit growth and mid-teens margins.

**【CFO Financial Commentary】**
- **Q2 Results**: Group comparable sales +1%, adjusted EBITA margin +130bps to 12.4%. Productivity savings €197M (€344M YTD) toward €800M 2025 target.
- **Segment Performance**: 
  - **D&T**: Sales -1% vs. high base, but margin +130bps to 13.5% from innovations and productivity.
  - **Connected Care**: Sales -1%, margin +160bps to 10.4% from efficiency gains.
  - **Personal Health**: Sales growth offset by EBITA margin decline (170bps) due to ad spend and mix.
- **Liquidity**: €1.8B cash, net debt €6.6B (2.2x leverage). €1B bond issuance at attractive rates.

**【Q&A Key Highlights】**
- **D&T Margin Drivers**: 130bps expansion from gross margin (innovations, SKU simplification) and productivity. Q3 margin may decline due to tariff timing.
- **Connected Care Decline**: Monitoring -1% vs. high base, but 6 U.S. partnerships and Respironics recovery driving Q3+ growth.
- **China Recovery**: PH destocking complete; Q2 sell-out up in festivals. Medical equipment tenders slow but improving.
- **Tariff Outlook**: 2026 impact annualized from Q3 2025 levels; long-term strategy includes tariff mitigation in new product designs.
- **Market Share**: North America Monitoring gaining share via efficiency solutions; D&T innovations (e.g., Azurion Neuro Biplane) winning 80%+ of Biplane orders.

Koninklijke Philips N.V. (PHG) Q2 2025 Earnings Call Transcript

- **Revenue Resilience**: Q1 sales beat expectations, with Personal Health returning to growth (+1%) outside China and North America orders up double-digit.
- **Tariff Mitigation**: €250-300M annual cost net of actions like US supply chain expansion and inventory phasing. Order book momentum intact despite macro uncertainty.
- **AI Innovation Edge**: 50% of sales from AI-driven products, with new MRI and CT platforms driving gross margin improvement.
- **China Strategy**: Completing PH destocking in Q2, positioning for H2 growth. Ultrasound VM platform counters VBP pressure with AI differentiation.
- **Margin Guidance**: EBITA margin 10.8-11.3% for 2025 (down 100bps), supported by productivity savings and innovation value.

**【CEO Summary Section】**
- **Q1 Performance Overview**: Order intake grew 4% (excluding China's double-digit decline), driven by North America (double-digit growth) and Diagnosis & Treatment (mid-single-digit globally). Personal Health returned to growth (+1% comparable) outside China.
- **Tariff Impact & Mitigation**: Announced tariffs net of mitigations expected to cost €250-300M annually. Actions include US supply chain optimization, inventory management, and selective pricing. Order book momentum remains strong despite macro uncertainty.
- **Innovation Highlights**: 50% of sales from AI-driven innovations (e.g., CT-5300, SmartSpeed MRI). New ultrasound VM platform in China shows traction despite VBP pressure.
- **2025 Outlook**: Sales growth 1-3%, EBITA margin 10.8-11.3% (down 100bps vs prior guidance). Free cash flow slightly positive after €1B Respironics settlement.

**【CFO Financial Commentary】**
- **Q1 Results**: Group sales -2% (vs +1-3% full year target), EBITA margin 8.6% (down 80bps). Personal Health growth (+1%) offset China decline. Gross margin improved due to innovation and productivity.
- **Tariff Financial Impact**: €250-300M net cost, primarily from US-China flows. Gross impact higher but mitigations (e.g., duty drawbacks, inventory phasing) reduce burden. Free cash flow guidance cut to slightly positive due to tariff timing.
- **Productivity & Costs**: €147M savings in Q1, on track for €800M annual target. Restructuring costs stable at €143M (aligned with expectations).

**【Q&A Highlights】**
- **Tariff Mitigation Details**: Half of €250-300M impact from inventory management and exemptions. US supply chain expansion (e.g., Minnesota manufacturing) underway but phased.
- **China Dynamics**: Personal Health destocking completes in Q2, enabling mechanical growth in H2. Ultrasound VM platform counters VBP pressure with AI-driven differentiation.
- **PH Growth Drivers**: International regions (Europe, Latin America) up double-digit. US growth modest but stable. No pull-forward demand from tariffs; focus on innovation (e.g., HealthSuite AI) to drive margins.
- **Margin Outlook**: EBITA margin resilience in Connected Care (3.5%) and D&T (9.5%) despite tariffs. Long-term margin expansion via productivity, innovation, and portfolio simplification.

Koninklijke Philips N.V. (PHG) Q1 2025 Earnings Call Transcript

- **2024 Performance**: 1% comparable sales growth, 11.5% adjusted EBITA margin, €1.3 billion Q4 free cash flow. China sales down double-digit, offset by 5% growth elsewhere.
- **2025 Outlook**: 1-3% sales growth, 30-80bp margin expansion to 11.8-12.3%. China decline mid- to high-single digits in H1, easing in H2.
- **Key Drivers**: AI innovation (50% sales from new products), Connected Care margin rebound (9.6% in 2024), and €2.5 billion productivity savings.
- **China Risks**: Consumer demand subdued, slow hospital tender execution. 2025 guidance cautious on first-half recovery.
- **Dividend Policy**: €0.85/share, up to 50% in cash, balancing returns with Respironics settlement payments.
- **S&R Recovery**: US market re-entry pending FDA approval. Global S&R orders up, with new mask launches and France market access.


**【CEO Opening Remarks】**
- Q4 and full-year 2024 results highlight strong profitability improvement and cash flow generation. Comparable sales grew 1% in Q4 and 1% for the full year, driven by 5% growth outside China, offset by double-digit declines in China. Orders grew 2% in Q4 and 1% for the year, with solid momentum in the US and growth regions.
- Gross margin improved by 90 basis points to 11.5% for the full year, supported by operational efficiency and productivity savings of €1.7 billion over two years. 
- 2025 outlook: 1-3% comparable sales growth, with mid- to high-single-digit decline in China, and margin expansion of 30-80 basis points to 11.8-12.3%.
- Key initiatives: AI-driven innovation (50% of sales from new products), regional supply chain diversification, and cost optimization to counter macro challenges.

**【CFO Financial Breakdown】**
- **Diagnosis & Treatment (D&T):** Q4 sales down 1%, full-year up 1%. Adjusted EBITA margin improved 170 basis points to 12.1%, driven by product mix, pricing, and productivity. Ultrasound and MR innovations (e.g., VM 11, helium-free MRI) contributed to high-single-digit order growth.
- **Connected Care:** Q4 sales up 7% (low base due to 2023 provision). Full-year sales up 2%, with Enterprise Informatics and Sleep & Respiratory Care returning to profitability. Margin improved 240 basis points to 9.6%.
- **Personal Health:** Q4 sales down 2%, full-year down 1%. Adjusted EBITA margin at 18% (Q4) and 16.7% (full year), supported by disciplined cost management.
- **Free Cash Flow:** €1.3 billion in Q4, €0.9 billion for the year, in line with guidance. €1.1 billion payment for US Respironics settlements expected in H1 2025.
- **Dividend:** Proposed €0.85 per share, with up to 50% in cash, balancing shareholder returns with liquidity needs.

**【Q&A Highlights】**
- **China Dynamics:** First-half 2025 sales expected to decline mid- to high-single digits, driven by consumer weakness and slow hospital CapEx. Second-half easing of comparison base may limit recovery. D&T orders outside China grew double-digit in Q4, offsetting China decline.
- **Cost Savings:** Productivity savings target increased to €2.5 billion (€800 million in 2025), focusing on simplifying operations, procurement, and R&D efficiency. Innovation spend protected to maintain pipeline (e.g., AI in imaging, Connected Care).
- **Tariffs & Supply Chain:** Regionalizing supply chains to mitigate US-China trade risks. No direct manufacturing in Mexico/Canada, but advocating for reliable global health tech supply chains.
- **Margin Expansion:** Back-end loaded in 2025 due to China phasing and royalty impacts. D&T margin improvement driven by high-margin modalities (IGT, MR) and innovation uptake.
- **Respironics Update:** US medical monitoring and personal injury settlements finalized. S&R business gaining momentum outside the US, with new mask approvals and France market re-entry.


Actual																														0.2836	0.4148	0.4137	0.5778
Forecast																														0.2054	0.3158	0.3697	0.5952
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+38.07%	+31.35%	+11.90%	-2.92%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	4.65B	5.00B	4.94B	6.08B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	4.35B	5.01B	5.04B	5.97B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+6.81%	-0.20%	-1.94%	+1.81%

PHG

PHG fundamentals

PHG Q4 2025 Earnings

Earnings Call

You can ask Aime

PHG

PHG fundamentals

PHG Q4 2025 Earnings

Earnings Call

PHG Earnings Call Summary for Q4/20253:00 AM on Feb 10, 2026

PHG Earnings Call Summary for Q3/202511:00 AM on Nov 4, 2025

PHG Earnings Call Summary for Q2/20253:00 AM on Jul 29, 2025

PHG Earnings Call Summary for Q1/20254:00 AM on May 6, 2025

PHG Earnings Call Summary for Q4/20244:00 AM on Feb 19, 2025

You can ask Aime